PT  - JOURNAL ARTICLE
AU  - J S Ross
AU  - K Wang
AU  - O R Elkadi
AU  - A Tarasen
AU  - L Foulke
AU  - C E Sheehan
AU  - G A Otto
AU  - G Palmer
AU  - R Yelensky
AU  - D Lipson
AU  - J Chmielecki
AU  - S M Ali
AU  - J Elvin
AU  - D Morosini
AU  - V A Miller
AU  - P J Stephens
TI  - Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
AID  - 10.1136/jclinpath-2014-202447
DP  - 2014 Sep 01
TA  - Journal of Clinical Pathology
PG  - 772--776
VI  - 67
IP  - 9
4099  - http://jcp.bmj.com/content/67/9/772.short
4100  - http://jcp.bmj.com/content/67/9/772.full
SO  - J Clin Pathol2014 Sep 01; 67
AB  - Aims Small cell lung cancer (SCLC) carries a poor prognosis, and the systemic therapies currently used as treatments are only modestly effective, as demonstrated by a low 5-year survival at only ∼5%. In this retrospective collected from March 2013 to study, we performed comprehensive genomic profiling of 98 small cell undifferentiated lung cancer (SCLC) samples to identify potential targets of therapy not currently searched for in routine clinical practice. Methods DNA from 98 SCLC was sequenced to high, uniform coverage (Illumina HiSeq 2500) and analysed for all classes of genomic alterations. Results A total of 386 alterations were identified for an average of 3.9 alterations per tumour (range 1–10). Fifty-two (53%) of cases harboured at least 1 actionable alteration with the potential to personalise therapy including base substitutions, amplifications or homozygous deletions in RICTOR (10%), KIT (7%), PIK3CA (6%), EGFR (5%), PTEN (5%), KRAS (5%), MCL1 (4%), FGFR1 (4%), BRCA2, (4%), TSC1 (3%), NF1 (3%), EPHA3 (3%) and CCND1. The most common non-actionable genomic alterations were alterations in TP53 (86% of SCLC cases), RB1 (54%) and MLL2 (17%). Conclusions Greater than 50% of the SCLC cases harboured at least one actionable alteration. Given the limited treatment options and poor prognosis of patients with SCLC, comprehensive genomic profiling has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease.